Immunocore Holdings plc American Depositary Receipt (IMCR)
Immunocore: KIMMTRAK Is Becoming A Cash Engine For A Much Larger TCR Platform
Immunocore has transitioned from a rare-disease oncology company to a self-funded platform company with a validated commercial engine. KIMMTRAK's strong global sales, five-year survival data, and operating leverage underpin IMCR's ability to fund a broad pipeline without dilutive equity. Upcoming catalysts include pivotal readouts for tebentafusp and brenetafusp in melanoma, PRAME franchise expansion, and initial data in oncology, infectious disease, and autoimmune programs.
Is it a Good Idea to Invest in Immunocore Stock Right Now?
IMCR is seeing strong Kimmtrak sales growth and pursuing label expansion studies that could broaden its reach across melanoma treatments.
4 Biotech Stocks Investors Should Watch in 2026
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position LQDA, IMNM, STOK and IMCR well in this volatile sector.
Wall Street Analysts Think Immunocore (IMCR) Could Surge 111.53%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 111.5% in Immunocore (IMCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Immunocore Holdings plc (IMCR) Q4 2025 Earnings Call Transcript
Immunocore Holdings plc (IMCR) Q4 2025 Earnings Call Transcript
Immunocore (IMCR) Upgraded to Strong Buy: Here's Why
Immunocore (IMCR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Immunocore (IMCR) Soars 5.9%: Is Further Upside Left in the Stock?
Immunocore (IMCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Immunocore Holdings plc (IMCR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Immunocore Holdings plc (IMCR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Immunocore (IMCR) Upgraded to Strong Buy: Here's What You Should Know
Immunocore (IMCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Immunocore: Continuing To Improve The Bottom Line, But Needing A Big Catalyst
Immunocore still relies exclusively on sales of tebentafusp to fund operations. While these sales have supported the company, they have not been enough to achieve profitability. Current market sentiment says to "Hold" based on slowing sales growth, but this does not factor in the broad pipeline.
Immunocore (IMCR) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Immunocore (IMCR) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Immunocore Holdings plc (IMCR) Q2 2025 Earnings Call Transcript
Immunocore Holdings plc (NASDAQ:IMCR ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants & - Corporate Participant Bahija Jallal - CEO & Executive Director Clayton Robertson - Head of Investor Relations David Berman - Executive Vice President of Research Development Mohammed M. Dar - Senior VP of Clinical Development & Chief Medical Officer Ralph Torbay - Corporate Participant EVP of Commercial - Corporate Participant Travis A.
